跳至主要内容
临床试验/NCT00546624
NCT00546624已完成2 期

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Merck Sharp & Dohme LLC0 个研究点目标入组 38 人开始时间: 2002年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
38

研究概览

简要总结

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have been diagnosed with Generalized Anxiety Disorder
  • Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

排除标准

  • History of drug or alcohol abuse
  • Have previously participated in another study using MK0777

研究者

申办方类型
Industry
责任方
Sponsor

相似试验